H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target of $275.00. The company’s shares closed last Thursday at $260.97, close to its 52-week high of $263.58.
According to TipRanks.com, Fein has 0 stars on 0-5 stars ranking scale with an average return of -4.5% and a 37.3% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Amylyx Pharmaceuticals Inc, and Deciphera Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Vertex Pharmaceuticals with a $276.57 average price target, representing a 6.4% upside. In a report issued on March 22, Robert W. Baird also maintained a Buy rating on the stock with a $240.00 price target.
Based on Vertex Pharmaceuticals’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $2.07 billion and net profit of $770 million. In comparison, last year the company earned revenue of $1.63 billion and had a net profit of $604 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Based in Massachusetts and incorporated in 1989, Vertex Pharmaceuticals, Inc. is a biopharmaceutical company, which is engaged in the development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.
Read More on VRTX:
- H.C. Wainwright Maintains a Hold Rating on Metacrine (MTCR)
- What Made H.C. Wainwright Downgrade Silverback Therapeutics’ Stock?
- H.C. Wainwright Maintains a Buy Rating on Corcept Therapeutics (CORT)
- H.C. Wainwright Keeps Their Buy Rating on ATAI Life Sciences (ATAI)
- Arcimoto (FUV) Receives a Rating Update from a Top Analyst